Friday, July 10, 2026

pharma · Ependymoma, Medulloblastoma · chronically occluded coronary artery

Ishita Pharma -

ISTA Pharma is a pharma organization headquartered in GB. Primary therapeutic focus areas include Ependymoma, Medulloblastoma, chronically occluded coronary artery, Hereditary Angioedema, Acute kidney injury, knee osteoa

Mumbai, IN HQ
3 Employees
EMA registrant Type
Company details
Status
Public
HQ
Mumbai, IN
Employees
3
Programs
8
Drugs
19
Patents
0
Clinical program

MICROPREP III

Phase 3 · other · knee osteoarthritis

MICROPREP III for knee osteoarthritis is a Phase 3 program (other) at ISTA Pharma Limited with 1 ClinicalTrials.gov record(s).

Internal code MICROPREP III

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
ISTA Pharma Limited
Phase
Phase 3
Modality
other
Indication
knee osteoarthritis
Status
active
Trials
1